AMAG Pharma (AMAG) Posts Q4 EPS of $0.10 on Tax Reform Gain

AMAG Pharma (NASDAQ: AMAG) reported Q4 EPS of $0.10, which does not compare to the analyst estimate of ($0.43). Revenue for the quarter came in at $159.7 million versus the consensus estimate of $160.14 million. Net income in the fourth quarter of 2017 was driven primarily by a decrease in the deferred tax liability due to federal tax reform.

GUIDANCE:

AMAG Pharma sees FY2018 revenue of $500-560 million, versus the consensus of $522.8 million.

For earnings history and earnings-related data on AMAG Pharma (AMAG) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Algorhythm Holdings (RIME) Tops Q2 EPS by 54c
• SanDisk upgraded at JPMorgan after investor day; shares climb